Serum micrornas as tool to predict early response to benralizumab in severe eosinophilic asthma

Severe eosinophilic asthma poses a serious health and economic problem, so new therapy approaches have been developed to control it, including biological drugs such as benralizumab, which is a monoclonal antibody that binds to IL-5 receptor alpha subunit and depletes peripheral blood eosinophils rap...

Full description

Bibliographic Details
Authors: Cañas, José Antonio, Valverde-Monge, Marcela, Rodrigo Muñoz, José Manuel, Sastre, Beatriz, Gil Martínez, Marta, García-Latorre, Raquel, Rial, Manuel J., Gómez-Cardeñosa, Aida, Fernández-Nieto, Mar, Pinillos-Robles, Erwin J., Rodríguez-Nieto, María J., González Mangado, Nicolás, Sastre Domínguez, Joaquín, Pozo Abejón, María Victoria del
Format: article
Publication Date:2021
Country:España
Institution:Universidad Autónoma de Madrid
Repository:Biblos-e Archivo. Repositorio Institucional de la UAM
Language:English
OAI Identifier:oai:repositorio.uam.es:10486/698180
Online Access:http://hdl.handle.net/10486/698180
https://dx.doi.org/10.3390/jpm11020076
Access Level:Open access
Keyword:Benralizumab
Biologic treatment
MicroRNA
Severe eosinophilic asthma
Medicina
Description
Summary:Severe eosinophilic asthma poses a serious health and economic problem, so new therapy approaches have been developed to control it, including biological drugs such as benralizumab, which is a monoclonal antibody that binds to IL-5 receptor alpha subunit and depletes peripheral blood eosinophils rapidly. Biomarkers that predict the response to this drug are needed so that microRNAs (miRNAs) can be useful tools. This study was performed with fifteen severe eosinophilic asthmatic patients treated with benralizumab, and serum miRNAs were evaluated before and after treatment by semi-quantitative PCR (qPCR). Patients showed a clinical improvement after benralizumab administration. Additionally, deregulation of miR-1246, miR-5100 and miR-338-3p was observed in severe asthmatic patients after eight weeks of therapy, and a correlation was found between miR-1246 and eosinophil counts, including a number of exacerbations per year in these severe asthmatics. In silico pathway analysis revealed that these three miRNAs are regulators of the MAPK signaling pathway, regulating target genes implicated in asthma such as NFKB2, NFATC3, DUSP1, DUSP2, DUSP5 and DUSP16. In this study, we observed an altered expression of miR-1246, miR-5100 and miR-338-3p after eight weeks of benralizumab administration, which could be used as early response markers.

Similar Items